Purple Biotech (PPBT) Cash & Equivalents (2017 - 2021)

Purple Biotech (PPBT) has disclosed Cash & Equivalents for 5 consecutive years, with $10.9 million as the latest value for Q4 2021.

  • On a quarterly basis, Cash & Equivalents fell 3.17% to $10.9 million in Q4 2021 year-over-year; TTM through Dec 2021 was $10.9 million, a 3.17% decrease, with the full-year FY2021 number at $10.9 million, down 3.17% from a year prior.
  • Cash & Equivalents was $10.9 million for Q4 2021 at Purple Biotech, down from $11.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $11.2 million in Q4 2020 to a low of $3.9 million in Q4 2017.
  • A 5-year average of $7.1 million and a median of $5.2 million in 2018 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: fell 15.07% in 2019, then skyrocketed 156.49% in 2020.
  • Purple Biotech's Cash & Equivalents stood at $3.9 million in 2017, then skyrocketed by 30.81% to $5.2 million in 2018, then dropped by 15.07% to $4.4 million in 2019, then surged by 156.49% to $11.2 million in 2020, then fell by 3.17% to $10.9 million in 2021.
  • Per Business Quant, the three most recent readings for PPBT's Cash & Equivalents are $10.9 million (Q4 2021), $11.2 million (Q4 2020), and $4.4 million (Q4 2019).